|
Mutation Information
|
Mutation Site
|
L180M |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Relevant Drug
|
clevudine (CLV);entecavir (ETV) |
|
Country
|
Korea |
Literature Information
|
PubMed PMID
|
23322992
|
|
Disease
|
Chronic hepatitis B
|
|
Published Year
|
2012 |
|
Journal
|
World journal of gastroenterology |
|
Title
|
Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B. |
|
Author
|
Kim SB,Song IH,Kim YM,Noh R,Kang HY,Lee HIe,Yang HY,Kim AN,Chae HB,Lee SH,Kim HS,Lee TH,Kang YW,Lee ES,Kim SH,Lee BS,Lee HY |
|
Evidence
|
The virologic breakthrough in the clevudine group occurred in 9 (7.6%) patients at weeks 48 and 15 (12.7%) patients at week 96, which primarily corresponded to genotypic mutations of rtM204I and/or rtL180M.
|
|
|
HBV Mutation Detail Information